相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
Daniele Rossini et al.
BRITISH JOURNAL OF CANCER (2021)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
Anuj K. Patel et al.
ONCOLOGIST (2020)
Colorectal cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.
Ranju Gupta et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.
Jordan Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Eyal Meiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
Per Pfeiffer et al.
LANCET ONCOLOGY (2020)
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Salvatore Siena et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Chiara Cremolini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular characterization of cancers with NTRK gene fusions
Zoran Gatalica et al.
MODERN PATHOLOGY (2019)
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem et al.
ONCOLOGIST (2019)
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies
Gianluca Mauri et al.
CANCER TREATMENT REVIEWS (2019)
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
ONCOLOGIST (2019)
Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer
Michael A. Morse et al.
ONCOLOGIST (2019)
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Laura Fancello et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Tanios S. Bekaii-Saab et al.
LANCET ONCOLOGY (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions
Emiliano Cocco et al.
CANCER RESEARCH (2019)
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M. Henricks et al.
EUROPEAN JOURNAL OF CANCER (2019)
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study
Michel Ducreux et al.
EUROPEAN JOURNAL OF CANCER (2019)
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)
Herbert Hurwitz et al.
ONCOLOGIST (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
Veena Shankaran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Rona Yaeger et al.
CANCER CELL (2018)
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
Eric Van Cutsem et al.
EUROPEAN JOURNAL OF CANCER (2018)
Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients
Sarah Besora et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US
Christopher N. Graham et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M. Henricks et al.
LANCET ONCOLOGY (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Ursula Amstutz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
Alfredo Carrato et al.
EUROPEAN JOURNAL OF CANCER (2017)
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
Fernando Rivera et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Molecular Biomarkers for the Evaluation of Colorectal Cancer Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Antonia R. Sepulveda et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
Yasutoshi Kuboki et al.
LANCET ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study
Nikol Snoeren et al.
NEOPLASIA (2017)
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers A Secondary Analysis of 2 Randomized Clinical Trials
Frank A. Sinicrope et al.
JAMA ONCOLOGY (2017)
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
CHARTA: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer-Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.
Hans-Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study
Talita Costa et al.
CLINICAL COLORECTAL CANCER (2017)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)
T. Aparicio et al.
ANNALS OF ONCOLOGY (2016)
The Worse Prognosis of Right-Sided Compared with Left-Sided Colon Cancers: a Systematic Review and Meta-analysis
Masashi Yahagi et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2016)
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
K. Yamazaki et al.
ANNALS OF ONCOLOGY (2016)
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressionaEuro
R. Obermannova et al.
ANNALS OF ONCOLOGY (2016)
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study
G. Folprecht et al.
ANNALS OF ONCOLOGY (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study
Kuo-Hsing Chen et al.
BMC CANCER (2016)
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
Tobias Engel Ayer Botrel et al.
BMC CANCER (2016)
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
Antoine Adenis et al.
BMC CANCER (2016)
Better survival in right-sided versus left-sided stage I - III colon cancer patients
Rene Warschkow et al.
BMC CANCER (2016)
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
Tae Won Kim et al.
BRITISH JOURNAL OF CANCER (2016)
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis
Yu Guo et al.
CANCER INVESTIGATION (2016)
TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study
Takayuki Yoshino et al.
CLINICAL COLORECTAL CANCER (2016)
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer
Timothy Price et al.
EUROPEAN JOURNAL OF CANCER (2016)
Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours
Andrew Rowland et al.
EUROPEAN JOURNAL OF CANCER (2016)
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time
Carin A. T. C. Lunenburg et al.
EUROPEAN JOURNAL OF CANCER (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping Reply
Maarten J. Deenen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Maarten J. Deenen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
Eva Segelov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
Joohee Sul et al.
ONCOLOGIST (2016)
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
Roberto Moretto et al.
ONCOLOGIST (2016)
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
Mizuki Nishino et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer
Maria Carmen Riesco-Martinez et al.
JOURNAL OF ONCOLOGY PRACTICE (2016)
Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies
Colleen Lewis
CLINICAL JOURNAL OF ONCOLOGY NURSING (2016)
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
S. Iwamoto et al.
ANNALS OF ONCOLOGY (2015)
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer
M. Schirripa et al.
ANNALS OF ONCOLOGY (2015)
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G. Masi et al.
ANNALS OF ONCOLOGY (2015)
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
X. Liu et al.
BMC CANCER (2015)
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
T. J. Price et al.
BRITISH JOURNAL OF CANCER (2015)
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
A. Rowland et al.
BRITISH JOURNAL OF CANCER (2015)
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Johanna C. Bendell et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Marc Peeters et al.
CLINICAL CANCER RESEARCH (2015)
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
J. Randolph Hecht et al.
CLINICAL COLORECTAL CANCER (2015)
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
Filippo Pietrantonio et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis
Sheng-wen Wu et al.
DIAGNOSTIC PATHOLOGY (2015)
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Filippo Pietrantonio et al.
EUROPEAN JOURNAL OF CANCER (2015)
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
S. Y. Brule et al.
EUROPEAN JOURNAL OF CANCER (2015)
Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?
Bert H. O'Neil et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
Dominik P. Modest et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Fotios Loupakis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks et al.
LANCET ONCOLOGY (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Emanuele Valtorta et al.
MODERN PATHOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy
Mizuki Nishino et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Daniel A. Goldstein et al.
ONCOLOGIST (2015)
Value of bevacizumab in treatment of colorectal cancer: A meta-analysis
Chun-Ying Qu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis
Chun-Hui Cui et al.
ONCOTARGET (2015)
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Fotios Loupakis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
M. J. Sorich et al.
ANNALS OF ONCOLOGY (2015)
Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis
S. R. Berry et al.
ANNALS OF ONCOLOGY (2015)
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
T. Gruenberger et al.
ANNALS OF ONCOLOGY (2015)
Right- and left-sided colorectal cancers respond differently to cetuximab
Feng Wang et al.
CHINESE JOURNAL OF CANCER (2015)
Final results from a randomized phase 3 study of FOLFIRI +/- panitumumab for second-line treatment of metastatic colorectal cancer
M. Peeters et al.
ANNALS OF ONCOLOGY (2014)
Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT
H. S. Hochster et al.
ANNALS OF ONCOLOGY (2014)
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
Tomas Buchler et al.
BMC CANCER (2014)
The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials
E. Segelov et al.
BRITISH JOURNAL OF CANCER (2014)
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan plus /- targeted therapy
Dorte Lisbet Nielsen et al.
CANCER TREATMENT REVIEWS (2014)
KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
Harry H. Yoon et al.
CLINICAL CANCER RESEARCH (2014)
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch et al.
CLINICAL CANCER RESEARCH (2014)
Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin® Registry - Investigation of Effectiveness and Safety (ARIES) Observational Cohort Study
H. I. Hurwitz et al.
CLINICAL ONCOLOGY (2014)
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial
Josep Tabernero et al.
EUROPEAN JOURNAL OF CANCER (2014)
Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Managing Advanced Colorectal Cancer: Have We Reached the PEAK With Current Therapies?
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance)
Charles L. Loprinzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)
Adam M. Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
BRAFV600E Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis
Dong Chen et al.
PLOS ONE (2014)
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
Axel Grothey et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
X. Liu et al.
PHARMACOGENOMICS JOURNAL (2014)
Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort
Annie Fourrier-Reglat et al.
TARGETED ONCOLOGY (2014)
Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis
F. Wen et al.
ANNALS OF ONCOLOGY (2013)
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
S. Kubicka et al.
ANNALS OF ONCOLOGY (2013)
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
V. Martin et al.
BRITISH JOURNAL OF CANCER (2013)
The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials
Chao Lv et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials
Fausto Petrelli et al.
CLINICAL COLORECTAL CANCER (2013)
Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials
Fei Dai et al.
CLINICAL DRUG INVESTIGATION (2013)
BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis
C. Clancy et al.
COLORECTAL DISEASE (2013)
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis
Viswanath Reddy Belum et al.
INVESTIGATIONAL NEW DRUGS (2013)
Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis
Di Zhang et al.
JOURNAL OF CHEMOTHERAPY (2013)
Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A meta-analysis
Qi Xu et al.
JOURNAL OF DIGESTIVE DISEASES (2013)
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Paul Lochhead et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
Bernard Nordlinger et al.
LANCET ONCOLOGY (2013)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
David Cunningham et al.
LANCET ONCOLOGY (2013)
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
Matthew T. Seymour et al.
LANCET ONCOLOGY (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna et al.
LANCET ONCOLOGY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials
Herbert I. Hurwitz et al.
ONCOLOGIST (2013)
Bevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase Ill 'Stop and Go' Study Results - A Turkish Oncology Group Trial
Suayib Yalcin et al.
ONCOLOGY (2013)
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis
Salvatore Terrazzino et al.
PHARMACOGENOMICS (2013)
The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials
F. Petrelli et al.
TARGETED ONCOLOGY (2013)
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials
F. Petrelli et al.
ANNALS OF ONCOLOGY (2012)
Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups
Ligia Traldi Macedo et al.
BMC CANCER (2012)
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
R-D Hofheinz et al.
BRITISH JOURNAL OF CANCER (2012)
Long-Term Neurotoxicity Effects of Oxaliplatin Added to Fluorouracil and Leucovorin as Adjuvant Therapy for Colon Cancer: Results from National Surgical Adjuvant Breast and Bowel Project Trials C-07 and LTS-01
Kelley M. Kidwell et al.
CANCER (2012)
Survival Outcomes of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Treated in US Community Oncology
Thomas H. Cartwright et al.
CLINICAL COLORECTAL CANCER (2012)
Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: A systematic review and meta-analysis
Zhenjie Wu et al.
EUROPEAN JOURNAL OF CANCER (2012)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Carsten Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2012)
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
Claus-Henning Koehne et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Is There a Difference in Demography and Clinical Characteristics in Patients Treated With and Without Bevacizumab?
Holger Hartmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer
Jeffrey A. Meyerhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Registries and Randomized Trials in Assessing the Effects of Bevacizumab in Colorectal Cancer: Is There a Common Theme?
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
Sabine Tejpar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino et al.
LANCET ONCOLOGY (2012)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
Aimery de Gramont et al.
LANCET ONCOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
Gholamreza Safaee Ardekani et al.
PLOS ONE (2012)
Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1976 to 2005
Lee Cheng et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Infusion reactions to the chimeric EGFR inhibitor cetuximab-change to the fully human anti-EGFR monoclonal antibody panitumumab is safe
G. Resch et al.
ANNALS OF ONCOLOGY (2011)
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
N. Knijn et al.
BRITISH JOURNAL OF CANCER (2011)
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J. Cassidy et al.
BRITISH JOURNAL OF CANCER (2011)
The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS Status
Edith P. Mitchell et al.
CLINICAL COLORECTAL CANCER (2011)
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients
N. Knijn et al.
EUROPEAN JOURNAL OF CANCER (2011)
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
Michel Ducreux et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Treatment-Related Mortality With Bevacizumab in Cancer Patients A Meta-analysis
Vishal Ranpura et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Is the Postprogression Survival Time Really Not Shortened in the Bevacizumab-Containing Arms of Phase III Clinical Trials?
Piotr Potemski
JOURNAL OF CLINICAL ONCOLOGY (2011)
Is the Postprogression Survival Time Really Not Shortened in the Bevacizumab-Containing Arms of Phase III Clinical Trials? Reply
David W. Miles
JOURNAL OF CLINICAL ONCOLOGY (2011)
Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
David Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
Timothy J. Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
Gianluca Masi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial
Michel Ducreux et al.
LANCET ONCOLOGY (2011)
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
S. Welch et al.
ANNALS OF ONCOLOGY (2010)
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice
D. Santini et al.
ANNALS OF ONCOLOGY (2010)
BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome
Z. Saridaki et al.
BRITISH JOURNAL OF CANCER (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
Fotios Loupakis et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis
Michihiro Hayashi et al.
BMC SURGERY (2010)
KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine
Hanlin L. Wang et al.
ADVANCES IN ANATOMIC PATHOLOGY (2010)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M. Koopman et al.
BRITISH JOURNAL OF CANCER (2009)
Stereotactic body radiation therapy for liver metastases
Omar Dawood et al.
EUROPEAN JOURNAL OF CANCER (2009)
A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer
Yunfei Cao et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841
George P. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Benoist Chibaudel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer
Barbara Burtness et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer
Alberto Sobrero et al.
ONCOLOGY (2009)
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy
Marie-Christine Etienne-Grimaldi et al.
CLINICAL CANCER RESEARCH (2008)
Determinants of RASistance to anti-epidermal growth factor receptor agents
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
Emmanuel Mitry et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Oxaliplatin-related neurotoxicity: Interest of calcium-magnesium infusion and no impact on its efficacy
Laurence Gamelin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
Salvatore Artale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
Brigit Gruenberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study
Howard S. Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Potential regional differences for the tolerability profiles of fluoropyrimidines
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases
Srinevas K. Reddy et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger et al.
LANCET (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group
Rainer Porschen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
Miriam Koopman et al.
LANCET (2007)
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
Matthew T. Seymour et al.
LANCET (2007)
Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)
A. Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival
Won-Suk Lee et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab
D. Helbling et al.
ANNALS OF ONCOLOGY (2007)
Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: A case report
James Heun et al.
CLINICAL COLORECTAL CANCER (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis
Ming-Shian Tsai et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Asymptomatic colorectal cancer with un-resectable liver metastases: Immediate colorectal resection or up-front systemic chemotherapy?
Andrea Muratore et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity
Howard S. Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The continuum of care: A paradigm for the management of metastatic colorectal cancer
Richard M. Goldberg et al.
ONCOLOGIST (2007)
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
Eric Van Cutsem et al.
EUROPEAN JOURNAL OF CANCER (2006)
OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab
Peter S. Yoo et al.
CLINICAL COLORECTAL CANCER (2006)
Update on capecitabine in colorectal cancer
Hans-Joachim Schmoll et al.
ONCOLOGIST (2006)
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study
SR Alberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hepatic and extrahepatic colorectal metastases: When resectable, their localization does not matter, but their total number has a prognostic effect
D Elias et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
FA Scappaticci et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
G Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
FF Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
FF Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
HI Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases
TM Pawlik et al.
ANNALS OF SURGERY (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
E Van Cutsem et al.
BRITISH JOURNAL OF CANCER (2004)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions:: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer
L Gamelin et al.
CLINICAL CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma
PM Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer
J Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
F Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics
LK Mattison et al.
PHARMACOGENOMICS (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Trends in long-term survival following liver resection for hepatic colorectal metastases
MA Choti et al.
ANNALS OF SURGERY (2002)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
